På ét år udviste 0, 3 mg pegaptanib en statistisk signifikant behandlingsfordel for det primære effekt endepunkt, andelen af patienter der havde tabt mindre end 15 bogstaver i synsskarphed (prædefinerede samlede analyser, 0, 3 mg pegaptanib 70% versus simuleret behandling 55%, p = 0, 0001; EOP1003 pegaptanib 0, 3 mg 73% versus simuleret behandling 59%, p = 0, 0105; EOP1004 pegaptanib 0, 3 mg 67% versus simuleret behandling 52%, p = 0, 0031).
6 At one year, pegaptanib 0.3 mg exhibited a statistically significant treatment benefit for the primary efficacy endpoint; proportion of patients losing less than 15 letters of visual acuity (prespecified pooled analysis, pegaptanib 0.3 mg 70% versus Sham 55%, p = 0.0001; EOP 1003 pegaptanib 0.3 mg 73% versus Sham 59%, p = 0.0105; EOP1004 pegaptanib 0.3 mg 67% versus Sham 52%, p = .0031).